Eli Lilly & Company has recalled 119,539 boxes of Trulicity (dulaglutide) 0.75 mg/0.5 mL because the autoinjector pens actually contain a higher dose of 1.5 mg/0.5 mL. This labeling error means patients may unknowingly inject double the intended amount of medication. This recall affects 4-pack boxes distributed nationwide across the United States. Consumers should check their pens immediately and contact their healthcare provider before using the medication.
Patients using these mislabeled pens will receive twice the prescribed dose of dulaglutide, which may cause severe gastrointestinal side effects such as nausea, vomiting, and abdominal pain, and could lead to more serious metabolic issues.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.